SCHEMBL5046935

SCHEMBL5046935

COCCCn1c(-c2csc(C)n2)cc(C(=O)O)c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
RAB9A P51151 5/20 0.44
KDM4E B2RXH2 4/20 0.44
NPC1 O15118 3/20 0.44
HPGD P15428 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
TRPV4 Q9HBA0 1/20 0.41
KMT2A Q03164 4/20 0.40
MAPT P10636 4/20 0.40
MEN1 O00255 3/20 0.40
HTT P42858 2/20 0.40
LMNA P02545 2/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ECE1 P42892 3/20 0.39
KDM4A O75164 1/20 0.38
KDM4B O94953 1/20 0.38
KDM5C P41229 1/20 0.38
KDM5B Q9UGL1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5044308 0.83 ALDH1A1 (0.54) ALDH1A1RAB9AKDM4ENPC1HPGD
SCHEMBL5044289 0.82 KLKB1 (0.42) ALDH1A1KDM4EHPGDTRPV4KMT2A
SCHEMBL5043785 0.81 ALDH1A1 (0.48) ALDH1A1RAB9AKDM4ENPC1HPGD
SCHEMBL5047149 0.81 ALDH1A1 (0.42) ALDH1A1RAB9AKDM4ENPC1HPGD
SCHEMBL5043885 0.80 SREBF2 (0.48) ALDH1A1HPGDTRPV4MAPTL3MBTL1
SCHEMBL5043726 0.78 SMN1; SMN2 (0.53) ALDH1A1KDM4ESMN1; SMN2MAPTHTT
SCHEMBL5044005 0.77 LMNA (0.46) ALDH1A1RAB9AKDM4ENPC1SMN1; SMN2
SCHEMBL5044535 0.76 ALDH1A1 (0.53) ALDH1A1RAB9AKDM4ENPC1HPGD
SCHEMBL5048683 0.75 KLKB1 (0.44) ALDH1A1RAB9AKDM4ENPC1HPGD
SCHEMBL25062490 0.75 NOTUM (0.51) ALDH1A1RAB9AKDM4ENPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R ALDH1A1 959/4885RAB9A 1009/4885KDM4E 2916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.